Paradigm Recall – The Saga Continues
It seems ironic that Medtronic (NYSE:MDT) will send out an email to registered users of their Paradigm pumps when there is a flaw in the software program but when it comes to a real, possibly life threatening situation the company prefers old fashioned snail mail. This begs the question why the company did not email registered users to inform them about the Class II recall.
To Diabetic Investor this demonstrates just how badly Medtronic handled the recall. While the FDA may not require the company to use email to inform patients about the recall there are times when the company should do more than what the FDA requires. Although there is no way of knowing, Diabetic Investor suspects that had they used email along with letters it possible several adverse events could have been avoided.
Diabetic Investor is still investigating this situation and maintains our belief that there is a serious design flaw with the Paradigm line of pumps. We can only hope in the future the company uses every means possible to inform their patient population if another problem occurs.